Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis

키워드

참고문헌 (95)

1. Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
2. Shun-Chin Yang, "Understanding the role of neutrophils in acute respiratory distress syndrome", Biomedical Journal, 44(4), pp.439~446 (2021), Elsevier BV[DOI]
3. Akira S, "Pathogen recognition and innate immunity", Cell, 124, pp.783~801 (2006)
4. Scheuplein VA, "High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus", J Virol, 89, pp.3859~3869 (2015)
5. Al-Qahtani AA, "Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ", Oncotarget, 8, pp.9053~9066 (2017)
6. Hu W, "SARS-CoV regulates immune function-related gene expression in human monocytic cells", Viral Immunol, 25, pp.277~288 (2012)
7. Hu Y, "The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination", J Virol, 91, pp.e02143~16 (2017)
8. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
9. Chen G, "Clinical and immunological features of severe and moderate coronavirus disease 2019", J Clin Invest, 130, pp.2620~2629 (2020)
10. Ong EZ, "A dynamic immune response shapes COVID-19 progression", Cell Host Microbe, 27, pp.879~882 (2020)
11. Chen X, "Detectable serum severe acute respiratory syndrome coronavirus 2 viral load(RNAemia)is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019", Clin Infect Dis, 71, pp.1937~1942 (2020)
12. Gong J, "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 : a retrospective study", BMC Infect Dis, 20, pp.963~ (2020)
13. Zhou Z, "Heightened innate immune responses in the respiratory tract of COVID-19 patients", Cell Host Microbe, 27, pp.883~890 (2020)
14. Xiong Y, "Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19patients", Emerg Microbes Infect, 9, pp.761~770 (2020)
15. Vabret N, "Immunology of COVID-19 : current state of the science", Immunity, 52, pp.910~941 (2020)
16. Mehta P, "Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation : challenges and opportunities", Lancet Respir Med, 8, pp.822~830 (2020)
17. Williams AE, "Evidence for chemokine synergy during neutrophil migration in ARDS", Thorax, 72, pp.66~73 (2017)
18. Grommes J, "Contribution of neutrophils to acute lung injury", Mol Med, 17, pp.293~307 (2011)
19. ARDS Definition Task Force, "Acute respiratory distress syndrome : the Berlin Definition", JAMA, 307, pp.2526~2533 (2012)
20. Camp JV, "A role for neutrophils in viral respiratory disease", Front Immunol, 8, pp.550~ (2017)
21. Fox SE, "Pulmonary and cardiac pathology in African American patients with COVID-19 : an autopsy series from New Orleans", Lancet Respir Med, 8, pp.681~686 (2020)
22. Liu J, "Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage", J Transl Med, 18, pp.206~ (2020)
23. Wilk AJ, "A single-cell atlas of the peripheral immune response in patients with severe COVID-19", Nat Med, 26, pp.1070~1076 (2020)
24. Laforge M, "Tissue damage from neutrophil-induced oxidative stress in COVID-19", Nat Rev Immunol, 20, pp.515~516 (2020)
25. Klok FA, "Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19 : an updated analysis", Thromb Res, 191, pp.148~150 (2020)
26. Brinkmann V, "Neutrophil extracellular traps kill bacteria", Science, 303, pp.1532~1535 (2004)
27. Van Avondt K, "Mechanisms and disease relevance of neutrophil extracellular trap formation", Eur J Clin Invest, 48(Suppl 2), pp.e12919~ (2018)
28. Barnes BJ, "Targeting potential drivers of COVID-19 : neutrophil extracellular traps", J Exp Med, 217, pp.e20200652~ (2020)
29. Zuo Y, "Neutrophil extracellular traps in COVID-19", JCI Insight, 5, pp.e138999~ (2020)
30. Veras FP, "SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19pathology", J Exp Med, 217, pp.e20201129~ (2020)
31. Hussell T, "Alveolar macrophages : plasticity in a tissue-specific context", Nat Rev Immunol, 14, pp.81~93 (2014)
32. Tate MD, "Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice", J Virol, 84, pp.7569~7580 (2010)
33. Merad M, "Pathological inflammation in patients with COVID-19 : a key role for monocytes and macrophages", Nat Rev Immunol, 20, pp.355~362 (2020)
34. Schulert GS, "Pathogenesis of macrophage activation syndrome and potential for cytokinedirected therapies", Annu Rev Med, 66, pp.145~159 (2015)
35. Liao M, "Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19", Nat Med, 26, pp.842~844 (2020)
36. Eisenbarth SC, "Dendritic cell subsets in T cell programming : location dictates function", Nat Rev Immunol, 19, pp.89~103 (2019)
37. Braciale TJ, "Regulating the adaptive immune response to respiratory virus infection", Nat Rev Immunol, 12, pp.295~305 (2012)
38. Zhou R, "Acute SARS-CoV-2infection impairs dendritic cell and T cell responses", Immunity, 53, pp.864.e5~877.e5 (2020)
39. Arunachalam PS, "Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans", Science, 369, pp.1210~1220 (2020)
40. Artis D, "The biology of innate lymphoid cells", Nature, 517, pp.293~301 (2015)
41. van Eeden C, "Natural killer cell dysfunction and its role in COVID-19", Int J Mol Sci, 21, pp.6351~ (2020)
42. Zheng M, "Functional exhaustion of antiviral lymphocytes in COVID-19 patients", Cell Mol Immunol, 17, pp.533~535 (2020)
43. Song CY, "Immune dysfunction following COVID-19, especially in severe patients", Sci Rep, 10, pp.15838~ (2020)
44. Li M, "Elevated exhaustion levels of NK and CD8+T cells as indicators for progression and prognosis of COVID-19 disease", Front Immunol, 11, pp.580237~ (2020)
45. Jiang Y, "COVID-19 pneumonia : CD8+T and NK cells are decreased in number but compensatory increased in cytotoxic potential", Clin Immunol, 218, pp.108516~ (2020)
46. Wang W, "Definition and risks of cytokine release syndrome in 11 critically ill COVID-19 patients with pneumonia : analysis of disease characteristics", J Infect Dis, 222, pp.1444~1451 (2020)
47. Cifaldi L, "Inhibition of natural killer cell cytotoxicity by interleukin-6 : implications for the pathogenesis of macrophage activation syndrome", Arthritis Rheumatol, 67, pp.3037~3046 (2015)
48. André P, "Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells", Cell, 175, pp.1731.e13~1743.e13 (2018)
49. Li F, "Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice", Gastroenterology, 144, pp.392~401 (2013)
50. Hadjadj J, "Impaired type I interferon activity and inflammatory responses in severe COVID-19patients", Science, 369, pp.718~724 (2020)
51. Monticelli LA, "Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus", Nat Immunol, 12, pp.1045~1054 (2011)
52. Califano D, "IFN-γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells", Mucosal Immunol, 11, pp.209~219 (2018)
53. García M, "Innate lymphoid cell composition associates with COVID-19 disease severity", Clin Transl Immunology, 9, pp.e1224~ (2020)
54. Pellicci DG, "Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge", Nat Rev Immunol, 20, pp.756~770 (2020)
55. Gottschalk C, "The role of invariant natural killer T cells in dendritic cell licensing, cross-priming, and memory CD8+T cell generation", Front Immunol, 6, pp.379~ (2015)
56. Kok WL, "Pivotal advance : invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection", J Leukoc Biol, 91, pp.357~368 (2012)
57. van Wilgenburg B, "MAIT cells contribute to protection against lethal influenza infection in vivo", Nat Commun, 9, pp.4706~ (2018)
58. Loh L, "Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation", Proc Natl Acad Sci U S A, 113, pp.10133~10138 (2016)
59. Palomino-Segura M, "Early production of IL-17A by γδ T cells in the trachea promotes viral clearance during influenza infection in mice", Eur J Immunol, 50, pp.97~109 (2020)
60. Poccia F, "Anti-severe acute respiratory syndrome coronavirus immune responses : the role played by Vγ9Vδ2 T cells", J Infect Dis, 193, pp.1244~1249 (2006)
61. Jouan Y, "Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients", J Exp Med, 217, pp.e20200872~ (2020)
62. Carissimo G, "Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19", Nat Commun, 11, pp.5243~ (2020)
63. Lei L, "The phenotypic changes of γδ T cells in COVID-19 patients", J Cell Mol Med, 24, pp.11603~11606 (2020)
64. Tyznik AJ, "Distinct requirements for activation of NKT and NK cells during viral infection", J Immunol, 192, pp.3676~3685 (2014)
65. Liu Z, "Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2", J Med Virol, 92, pp.595~601 (2020)
66. Li F, "Structure of SARS coronavirus spike receptor-binding domain complexed with receptor", Science, 309, pp.1864~1868 (2005)
67. Roberts A, "A mouse-adapted SARS-coronavirus causes disease and mortality in BALB", c mice, 2007, pp.3, e5~
68. Page C, "Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection", J Virol, 86, pp.13334~13349 (2012)
69. Channappanavar R, "Dysregulated type I Interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoVinfected mice", Cell Host Microbe, 19, pp.181~193 (2016)
70. Zhao J, "Evasion by stealth : inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice", PLoS Pathog, 5, pp.e1000636~ (2009)
71. Wang J, "Mouse-adapted SARSCoV-2 replicates efficiently in the upper and lower respiratory tract of BALB", c and C57BL, Protein Cell, pp.2020, 11[DOI]
72. Gu H, "Adaptation of SARSCoV-2 in BALB", c mice for testing vaccine efficacy, 2020, pp.369, 1603~1607
73. Leist SR, "A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice", Cell, 183, pp.1070.e12~1085.e12 (2020)
74. Dinnon KH 3rd, "A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures", Nature, 586, pp.560~566 (2020)
75. Zheng J, "COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice", Nature, 589, pp.603~607 (2021)
76. Bao L, "The pathogenicity of SARSCoV-2 in hACE2 transgenic mice", Nature, 583, pp.830~833 (2020)
77. Israelow B, "Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling", J Exp Med, 217, pp.e20201241~ (2020)
78. Hassan AO, "A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies", Cell, 182, pp.744.e4~753.e4 (2020)
79. Winkler ES, "SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function", Nat Immunol, 21, pp.1327~1335 (2020)
80. Sia SF, "Pathogenesis and transmission of SARS-CoV-2 in golden hamsters", Nature, 583, pp.834~838 (2020)
81. Kim YI, "Infection and rapid transmission of SARS-CoV-2 in ferrets", Cell Host Microbe, 27, pp.704.e2~709.e2 (2020)
82. Shi J, "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2", Science, 368, pp.1016~1020 (2020)
83. Ryan KA, "Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity", Nat Commun, 12, pp.81~ (2021)
84. Lu S, "Effective treatment of SARSCoV-2-infected rhesus macaques by attenuating inflammation", Cell Res, 31, pp.229~232 (2021)
85. Chandrashekar A, "SARS-CoV-2 infection protects against rechallenge in rhesus macaques", Science, 369, pp.812~817 (2020)
86. Mercado NB, "Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques", Nature, 586, pp.583~588 (2020)
87. Shan C, "Infection with novel coronavirus(SARS-CoV-2)causes pneumonia in Rhesus macaques", Cell Res, 30, pp.670~677 (2020)
88. Zheng H, "Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques : a nonhuman primate model of COVID-19progression", PLoS Pathog, 16, pp.e1008949~ (2020)
89. Liu L, "Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection", JCI Insight, 4, pp.e123158~ (2019)
90. Clay C, "Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge", J Virol, 86, pp.4234~4244 (2012)
91. Rockx B, "Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model", Science, 368, pp.1012~1015 (2020)
92. Munster VJ, "Respiratory disease in rhesus macaques inoculated with SARS-CoV-2", Nature, 585, pp.268~272 (2020)
93. Yu P, "Age-related rhesus macaque models of COVID-19", Animal Model Exp Med, 3, pp.93~97 (2020)
94. Katsura H, "Human lung stem cell-based alveolospheres provide insights into SARS-CoV-2-mediated interferon responses and pneumocyte dysfunction", Cell Stem Cell, 27, pp.890.e8~904.e8 (2020)
95. Elbadawi M, "Organoids of human airways to study infectivity and cytopathy of SARS-CoV-2", Lancet Respir Med, 8, pp.e55~e56 (2020)

관련 논문AI추천